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Abstract
Background: Pediatric cancer patients face an increased risk of healthcare-associated infection
(HAI). To date, no prospective multicenter studies have been published on this topic.
Methods: Prospective multicenter surveillance for HAI and nosocomial fever of unknown origin
(nFUO) with specific case definitions and standardized surveillance methods.
Results: 7 pediatric oncology centers (university facilities) participated from April 01, 2001 to
August 31, 2005. During 54,824 days of inpatient surveillance, 727 HAIs and nFUOs were
registered in 411 patients. Of these, 263 (36%) were HAIs in 181 patients, for an incidence density
(ID) (number of events per 1,000 inpatient days) of 4.8 (95% CI 4.2 to 5.4; range 2.4 to 11.7; P <
0.001), and 464 (64%) were nFUO in 230 patients. Neutropenia at diagnosis correlated significantly
with clinical severity of HAI. Of the 263 HAIs, 153 (58%) were bloodstream infections (BSI). Of the
138 laboratory-confirmed BSIs, 123 (89%) were associated with use of a long-term central venous
catheter (CVAD), resulting in an overall ID of 2.8 per 1,000 utilization days (95% CI 2.3 to 3.3).
The ID was significantly lower in Port-type than in Hickman-type CVADs. The death of 8 children
was related to HAI, including six cases of aspergillosis. The attributable mortality was 3.0% without
a significant association to neutropenia at time of NI diagnosis.
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Conclusion: Our study confirmed that pediatric cancer patients are at an increased risk for
specific HAIs. The prospective surveillance of HAI and comparison with cumulative multicenter
results are indispensable for targeted prevention of these adverse events of anticancer treatment.
Background
Pediatric cancer patients have an increased risk of poten-
tially life-threatening infectious [1-4] complications due
to their underlying illnesses and intensive anticancer treat-
ment [5-7]. Most of these infections are bloodstream
infections (BSIs), most often associated with a central
venous access device (CVAD) [8]. Healthcare-associated
infections (HAIs) in pediatric cancer patients have been
investigated in only a few single-center studies [9-12].
One additional European study included two pediatric
oncology units [13] in a 6-month prospective survey using
periodic chart review during hospitalization, but did not
use adjusted definitions for immunocompromised pedi-
atric patients [14].
The exact proportion of HAIs in these high-risk patients is
unknown; two single-center prospective studies in pediat-
ric hematology-oncology patients, excluding allogenic
bone marrow transplantations, found an incidence of
20% [9] (ID 10.8/1,000 inpatient days) and 24% [10] (ID
17.7/1,000 inpatient days), respectively. One recent sin-
gle-center study found an ID of 38.9 HAIs per 1,000 inpa-
tient days in a pediatric stem-cell and bone-marrow
transplantation unit [12], but the corresponding protocol
referred only to patients with neutropenia [15].
In 1998, our group developed a module for the prospec-
tive unit-based surveillance of HAI in pediatric cancer
patients: Onkopaed NKI. The results of a prospective sin-
gle-center 10-month pilot study confirmed the feasibility
of this module as well as the high risk of HAI and CVAD-
associated BSIs in pediatric cancer patients [9]. The Onko-
paed NKI module has already been used for prospective
intervention studies on CVAD-associated infections [16],
the restricted use of glycopeptides as a component of
empirical antimicrobial therapy [17], and antifungal
prophylaxis with itraconazole [18]. We now present the
results of the multicenter prospective surveillance study
for HAI and nosocomial fever of unknown origin (nFUO)
in 7 German pediatric oncology centers from 2001
through 2005.
Methods
The Onkopaed NKI module [9] uses standard methods of
the Centers for Disease Control and Prevention (CDC;
Atlanta, GA) [19] for the prospective unit-based surveil-
lance of selected HAIs and nFUOs (occurring at least 24
hours after patients' admission) in pediatric cancer
patients. The most important outcome parameter, the ID
of events per 1,000 inpatient days, was calculated as the
number of events divided by all inpatient days times
1,000. The ID of events per 1,000 inpatient device utiliza-
tion days and the device utilization rate itself were calcu-
lated correspondingly. 'Multidrug-resistant isolates'
referred to bacterial pathogens in vitro resistant to at least
two of the corresponding first-line antimicrobials (ceftazi-
dime, ceftriaxone, aminoglycosides, piperacillin-tazo-
bactam). The surveillance module did not ask for
admissions or numbers of individual patients in the par-
ticipating institution during the surveillance period.
Inclusion Criteria
All inpatients treated for at least 24 hours on the partici-
pating pediatric oncology ward were consecutively
included in the unit-based surveillance study in terms of
inpatient days, device days, and transplantation days.
Data from patients who experienced at least one event
(HAI or nFUO) were entered into the database. The age of
the patient, malignancy and relapse status (first illness vs
relapse) were documented as well as the type of CVAD,
the presence of severe neutropenia at the time of event,
clinical symptoms, and certain outcome parameters
related to the type of HAI. The number of admissions to
the unit was not documented in this study.
Definitions
Fever was defined as body temperature > 38°C for more
than 4 hours or once > 38.5°C. Severe neutropenia was
defined as an absolute neutrophil count < 0.5 × 109/L or
as a decreasing leukocyte count < 1.0 × 109/L without a
differential count available.
Acute transplantation days were days with severe neutro-
penia following high dose chemotherapy as a condition-
ing regimen for autologous or allogenic stem-cell or bone-
marrow transplantation (SCT, BMT).
The CDC's system of definitions for HAI was adjusted to
the particular situation of this risk group of immunocom-
promized patients [14] (the complete definition set is
available electronically at [20]).
The reference values for the assessment of vital signs were
adjusted to the patient's age [21]. For all events, the two-
step validation concept of the Onkopaed NKI software
necessitated a consensus between the primary data man-
agement personnel (study nurse and infection control
personnel) and one of the attending pediatric oncologists.BMC Infectious Diseases 2008, 8:70 http://www.biomedcentral.com/1471-2334/8/70
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Attributes of BSI were severity in terms of bacteremia, sep-
sis, septic shock and septic shock with multiorgan failure
[21] and association with CVAD [8]. The term 'catheter-
associated bloodstream infection' referred to a BSI in a
patient with a central venous catheter in place without any
additional clinically or microbiologically confirmed focus
of infection. The EORTC consensus criteria were used for
the definition of invasive aspergillosis; only 'probable' or
'proven' cases were included in the analysis [22].
Clostridium difficile associated disease (CDAD) was
defined as symptoms of an abdominal infection starting
at least 48 hours after hospital admission, and with a pos-
itive C. difficile-toxin cell culture assay from at least one
stool specimen, leading to initiation of antimicrobial
treatment directed against C. difficile for at least 5 days.
Mortality attributable to HAI was defined as the propor-
tion of patients in whom the attending physicians stated
that the HAI had contributed to the fatal outcome.
Ethic Approval and Informed Consent
The study protocol was approved by the Ethics Committee
of the Medical Faculty, University of Bonn, Germany. The
patient or his/her legal guardians signed informed con-
sent for participation before any data were included in the
study. No patient or legal guardian refused participation.
Statistical Analyses
Poisson estimates and their exact 95% confidence inter-
vals (95%CIs) were calculated. The exact homogeneity of
Poisson rates test, the exact Fisher-Freeman Halton test,
Fisher's exact test, and exact Poisson regression were used
where appropriate (with inpatient days as rate multiplier,
performed to asses the evolution over time of HAI inci-
dence). Two-sided tests were applied throughout, and P-
values below 0.05 were considered significant. StatXact 6
and LogXact 6 software (both from Cytel Software Corp.,
Cambridge, MA, USA) were used for all analyses.
Results
Basic Data including Device Utilization
Seven pediatric oncology centers, all located at tertiary
care university facilities, and denoted as C1 to C7, partici-
pated in this study for at least 6 consecutive months from
April 01, 2001 to August 31, 2005. While C3 was a special-
ized unit for allogenic and autologous SCT and BMT, all
other units offered conventional chemotherapy and radi-
otherapy, as well as high dose chemotherapy and autolo-
gous SCT to their patients. The study covered a total of 204
months of prospective surveillance in the 7 centers. They
took part for 14, 53, 30, 6, 32, 41 and 28 months (C1 to
C7). In total, data on 54,824 inpatient days were col-
lected. The respective centers contributed 4%, 35%, 4%,
4%, 19%, 21% and 12% (C1 to C7) to these inpatient
days (Table 1 shows the number and proportion of acute
transplantation days).
The 7 centers differed significantly in the utilization rates
of any CVAD (mean cumulative rate × 100: 80; range 62
for C1 to 100 for C3; P < 0.001; Figure 1), of urinary cath-
eters (0 for C3 to 5.5 for C1; P < 0.001), and of CSF drain-
ages (0 for C3/4/6 to 1.1 for C5; P < 0.001). As shown in
Fig. 1, local preferences led to significantly different
CVAD-specific utilization rates (P < 0.001). Further basic
data, in particular those of cumulative device utilization
days, are given in Table 1.
Infections: Documented HAIs vs nFUOs
Of 727 events, 263 (36%; 181 patients) were HAIs and
464 (64%; 230 patients) were nFUOs. Table 2 lists patient
characteristics related to HAI vs nFUO events.
The age of patients with HAIs and nFUOs differed signifi-
cantly, with a relative excess of HAIs in patients at least 15
years old. Besides, there was a significant relative excess of
HAI in patients with relapsed malignancies. Neither
malignancy diagnosis nor treatment modality preceding
the event differed significantly between HAIs and nFUOs.
The 727 events recorded during 54,824 inpatient days
resulted in an estimated overall ID of 13.3 events per
1,000 inpatient days (95% CI 12.3 to 14.3). The event IDs
differed significantly among the 7 centers (range 7.4 for
C1 to 23.0 for C3; P < 0.001), as did the ID of HAI (overall
estimate 4.8; 95% CI 4.2 to 5.4; range 2.4 for C7 to 11.7
for C3; P < 0.001), and of nFUOs (8.5; 7.7 to 9.3; 3.9 for
C1 to 11.3 for C3; P = 0.001; Figure 2). Except for C3,
where HAI accounted for 51% of all documented events,
the other centers concordantly documented more nFUOs
than HAIs. C3 reported 27 HAIs in 30 months of prospec-
tive surveillance, with 3 HAIs during 91 days with severe
neutropenia after autologous SCT and 24 HAIs during
751 days in severe neutropenia following allogenic SCT or
Table 1: Number of surveillance days by risk category
Category Days
Total inpatient days 54,824
Stem cell transplantation (autologous)# 1,041
Stem cell transplantation (allogenic)# 751
Total CVAD days 44,094
- Non-tunneled CVAD 1,143
- Port-type 15,600
- Broviac/Hickman 27,351
External CSF drainage days 187
Urinary catheter days 1,045
CVAD = central venous access device; CSF = cerebrospinal fluid 
(ventricle)
# Days with a total granulocyte count < 0.5 × 109/LBMC Infectious Diseases 2008, 8:70 http://www.biomedcentral.com/1471-2334/8/70
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BMT, for a local HAI ID of 33 after autologous, and of 32
after, allogenic transplantation. In the remaining centers,
the ID of nosocomial infections/1,000 acute autologous
transplantation days with neutropenia ranged from 0.0
(C7; 180 days, 0 HAI) to 47.4 (C2; 211 days, 10 HAI).
Table 2: Basic characteristics of healthcare-associated infections (HAIs) and of nosocomial fevers of unknown origin (nFUO)
Item HAI (N = 263) nFUO (N = 464) P-value
Number of patients included (in total, n = 411) 181 230 -
Age at diagnosis of HAI/nFUO < 0.001
< 5 years 84 (32%) 174 (38%)
5 years to < 10 years 58 (22%) 130 (28%)
10 years to < 15 years 56 (21%) 99 (21%)
≥ 15 years 65 (25%) 61 (13%)
Underlying disease 0.07
Acute lymphoblastic leukemia 86 (33%) 136 (29%)
Acute myeloid leukemia 34 (13%) 40 (9%)
Lymphoma 29 (11%) 48 (10%)
solid tumor outside central nervous system 70 (27%) 166 (36%)
solid tumor of central nervous system 34 (13%) 65 (14%)
non-malignant hematologic disease 10 (4%) 9 (2%)
Relapse of malignancy 54 (21%) 68 (15%) 0.049
Therapy§ preceding HAI/nFUO 0.18
conventional chemotherapy 214 (81%) 391 (84%)
high-dose chemotherapy & autologous SCT 22 (8%) 44 (9%)
high-dose chemotherapy & allogeneic SCT 26 (10%) 25 (5%)
radiation therapy 14 (5%) 22 (5%)
Neutropenia at diagnosis of HAI/nFUO 145 (55%) 232 (50%) 0.19
Indicated are numbers (proportion of respective events).
§Since more than one treatment modality was applicable, the numbers do not add up to 263 and 464, respectively.
Device utilization rates (inpatient utilization days/inpatient days) for the different central venous access devices (CVADs) in the  participating centers (C1-C7) Figure 1
Device utilization rates (inpatient utilization days/inpatient days) for the different central venous access 
devices (CVADs) in the participating centers (C1-C7). CVC = conventional non-tunneled central venous access. Port = 
Port type CVAD with subcutaneously implanted reservoir. Broviac/Hickman = tunneled long term CVAD with subcutaneous 
cuff.BMC Infectious Diseases 2008, 8:70 http://www.biomedcentral.com/1471-2334/8/70
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Presence of Severe Neutropenia at Diagnosis of the HAI
The proportion of patients with severe neutropenia at the
time of the event did not differ between HAIs and nFUOs
(Table 2). All patients with blood-culture positive septic
shock (N = 5) and blood-culture positive sepsis with mul-
tiorgan failure (N = 3) had presented with severe neutro-
penia, as did 83% of those with blood-culture positive
sepsis (29 of 35), 80% with clinically documented sepsis
(8 of 10, blood culture negative), 73% with invasive
aspergillosis (19 of 26), and 52% with bacteremia (49 of
95). In patients with surgical site infections, pneumonia
or Clostridium difficile-associated disease, the proportion
of patients with neutropenia at the onset of the infection
was 27%, 55% and 29%, respectively.
Healthcare-associated infections: Etiology and Resistances
Of the 263 HAIs, 153 (58%) were BSIs (see Table 3 for
details). Of the 138 blood-culture positive BSIs, 123
(89%) were associated with a CVAD, resulting in an over-
all ID of 2.8 per 1,000 utilization days (95% CI 2.3 to
3.3). The IDs were significantly different for the 3 types of
CVADs: The ID was 5.2 in non-tunneled, short-term
CVADs (95% CI 1.9 to 11.4; 6 events in 1,143 days), 1.8
in Port-type CVADs (1.2 to 2.6; 28 events in 15,600 days),
and 3.3 in Broviac/Hickman catheters (2.6 to 4.0; 89
events in 27,351 days; P = 0.009). Only 15 (11%) of all
BSI were secondary cases related to an identified source
other than the CVAD. This corresponds to an ID of 0.27
secondary BSIs per 1,000 inpatient days. In 15 (13%) of
114 blood culture positive, CVAD-associated BSIs, the
device was removed because of the infection (Port-type 7
of 28; Broviac/Hickman 8 of 86).
In the 138 blood-culture positive BSIs, 145 isolates out of
25 pathogenic species (144 bacteria and 1 Candida albi-
cans) were detected. Seven BSIs (5%) were polymicrobial,
and 62% of all isolates were Gram positive (Table 4).
Coagulase-negative staphylococci (CoNS; 38% of them
MRSE) were the most prevalent pathogens (34%). In
addition to the 19 MRSE, only 4 (3%) of all isolates were
multiresistant, with two vancomycin-resistant enterococci
(VRE), one multiresistant Klebsiella spp. and one multire-
sistant Pseudomonas aeruginosa.
Twenty cases of radiologically confirmed nosocomial
pneumonia were reported. None of these patients had
been mechanically ventilated in the week before the
event, and no additional risk factors were detected. In
only one case of pneumonia could a causal pathogen be
identified (Acinetobacter baumanii, detected in a broncho-
alveolar lavage sample).
In the 26 reported cases of invasive aspergillosis, patients
had been hospitalized for a median duration of 16 days
(range 3 to 64). Only 2 respiratory syncytial virus (RSV)
infections were reported from a single center (C2).
There were 16 pathogens detected related to the 15 surgi-
cal-site infections (SSIs), the most prevalent were Staphy-
lococcus aureus (n = 7; 1 of these MRSA) and CoNS (n = 5;
2 of these MRSE). The other pathogens were Escherichia
coli, Enterobacter cloacae, Enterococcus faecium, and K. pneu-
moniae (one each). The median time from the operation to
the diagnosis of SSI was 16 days (IQR 10–28 days). Five
SSIs (30%) were related to a local infection of a central
venous access device. In 7 of 15 SSIs (47%) treatment
included second surgical intervention. One SSI (7%) was
related to an orthopedic implant (osteosarcoma, femur, S.
aureus infection).
In total, 24 cases of CDAD were reported. In 3 patients,
surgical interventions were necessary during the clinical
course of the acute intra-abdominal infection. In C6, 9 out
of 13 cases were reported from June, 2001 to January,
2001, for an incidence density of 3.79 (9 events in 2,376
inpatient days). After the local preventive measures were
reorganized, the ID decreased to 0.44 (4 cases in 9,077
days).
Six cases of rotavirus gastroenteritis were reported in
patients with a median age of 2.9 years (range 1.2 to
12.6). Five of these required intravenous hydration and 2
Incidence density of 263 healthcare associated infections and  464 nosocomial fevers of unknown origin in the participating  centers (C1-C7) Figure 2
Incidence density of 263 healthcare associated infec-
tions and 464 nosocomial fevers of unknown origin in 
the participating centers (C1-C7). Q75 = 75. percentile 
excluding data from center 3 (allogenic transplantation unit).BMC Infectious Diseases 2008, 8:70 http://www.biomedcentral.com/1471-2334/8/70
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experienced severe disturbances of electrolyte balance
resulting in parenteral interventions. Of the 8 urinary tract
infections reported, only 3 were catheter-related, for an ID
of 2.9/1,000 device utilization days. A single case of a ven-
triculits/meningitis by CoNS related to external CSF drain-
age after CNS tumor surgery was reported, for an ID of
5.4/1,000 utilization days.
With 8 of 263 children's deaths attributed to an HAI, the
overall attributable mortality was 3.0%. Severe neutrope-
nia at time of HAI was not associated with a fatal outcome
(3 of 145 patients with, vs 5 of 118 without, severe neutro-
penia; P = 0.47). Six of these fatal outcomes were observed
in patients with invasive aspergillosis (4 pulmonary and 2
cerebral), the other 2 fatal outcomes were in patients with
blood-culture negative septic shock with multiorgan fail-
ure.
Overall, there was a significant 16% reduction of HAI ID
per year (odds ratio per year of study participation: 0.84;
95% exact CI 0.75 to 0.95; P = 0.005). Analyzing each
center separately, there was a significant decrease in HAIs
over time only in center 2 (0.75; 0.64 to 0.88; P < 0.001;
Figure 3).
Discussion
This study is the first prospective multicenter surveillance
study of HAI in pediatric cancer patients using standard-
ized CDC methods and adjusted consensus definitions for
this special patient population. Our study confirms that
pediatric cancer patients are at an increased risk for spe-
cific HAI. These adverse events can result not only in sig-
nificant morbidity and mortality, but also in an increased
expenditure of limited financial and personnel resources.
In particular, CVAD-associated BSI, which represent the
majority of all HAIs in this population, should be targeted
to improve clinical practices and evaluate new preventive
strategies [23].
Although associated with a severe clinical course, a signif-
icant proportion of all patients with HAI did not have
neutropenia at the time of diagnosis. This is in agreement
with results from other groups who found severe CVAD-
related infections in pediatric cancer patients in the
Table 3: Distribution and incidence densities of 263 HAI
Kind of healthcare-associated infection (HAI) No. (Proportion) ID
All HAIs 263 (100%) 4.80
Bloodstream infections (BSI) 153 (58%) 2.79
Laboratory-confirmed (blood-culture positive) BSI 138 (52%) 2.52
Bacteremia 95 (36%) 1.73
Sepsis 35 (13%) 0.64
Septic shock 5 (2%) 0.09
Septic shock with multiorgan failure 3 (1%) 0.05
Blood-culture negative BSI 15 (6%) 0.27
Clinically defined sepsis 10 (4%) 0.18
Clinically defined septic shock 1 (0%) 0.02
Clinically defined septic shock with multiorgan failure 4 (2%) 0.07
Radiologically confirmed pneumonia 20 (8%) 0.36
Invasive aspergillosis 26 (10%) 0.47
Pulmonary invasive aspergillosis 21 (8%) 0.38
Proven pulmonary case of invasive aspergillosis 6 (2%) 0.11
Probable pulmonary case of invasive aspergillosis 15 (6%) 0.27
Other localization (sinus, central nervous system) 5 (2%) 0.09
Respiratory syncytial virus (RSV) infection 2 (1%) 0.04
Surgical site infection 15 (6%) 0.27
Early (≤ 14 days from intervention) surgical site infection 6 (2%) 0.11
Late (> 14 days from intervention) surgical site infection 9 (3%) 0.16
Clostridium difficileassociated enterocolitis 24 (9%) 0.44
Preceding i.v. antibiotics within 14 days 11 (4%) 0.20
No preceding i.v. antibiotics within 14 days 13 (5%) 0.24
Rotavirus associated enterocolitis 6 (2%) 0.11
Urinary tract infection (UTI) 8 (3%) 0.15
UTI related to urinary tract catheter 3 (1%) 0.05
UTI not related to urinary tract catheter 5 (2%) 0.09
Ventriculitis related to external CSF drainage 1 (0%) 0.02
Local infections at the central venous access device exit site 8 (3%) 0.15
No. indicates the absolute number; ID indicates incidence density per 1,000 inpatient daysBMC Infectious Diseases 2008, 8:70 http://www.biomedcentral.com/1471-2334/8/70
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absence of neutropenia [24]. As a consequence, surveil-
lance should not be limited to the period of neutropenia,
and for the calculation of IDs days of neutropenia should
not be used as the (sole) denominator.
Even in those patients who have received an allogenic
BMT or SCT, the clinical relevance of certain late onset
infections (BSIs or invasive fungal infections after the
recovery of the leukocyte count have been observed) [7]
argues against a surveillance that is restricted to early 'neu-
tropenic' HAI.
The IDs described in our study are within the range of
those from single-center studies. During 3 months of sur-
veillance in 52 pediatric cancer patients with 135 admis-
sions and 1,017 inpatient days, Urrea et al. [10] found a
HAI rate of 23.5%, an incidence of 13.3/100 admissions
and an ID of 17.7 per 1,000 patient days. In the pilot
study of the Oncopaed NKI module [9], we investigated
40 HAIs in 28 out of 143 patients (HAI rate 19.6%) hos-
pitalized for 3,701 days (776 admissions) during a 10-
month prospective surveillance period. The HAI incidence
was 5.2/100 admissions and the overall ID of HAI was
10.8 per 1,000 inpatient-days. The overall CVAD-related
BSI rate was 7.4 per 1,000 inpatient utilization days.
In the transplantation unit (C3), patients after an autolo-
gous STC had the same ID for HAI as those after allogenic
Incidence density of HAI over time in Center 2 (48 months  of surveillance divided in 8 consecutive periods of 6 months) Figure 3
Incidence density of HAI over time in Center 2 (48 
months of surveillance divided in 8 consecutive peri-
ods of 6 months).
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Table 4: Distribution of 145 pathogens in 138 laboratory-confirmed BSIs
Isolate No of Isolates (n = 145)
CoNS (of these: methicillin-resistant) 50 (MRSE: 19)
Escherichia coli 22
α-hemolytic streptococci (Str. viridans) 21
Klebsiella pneumoniae 9
Pseudomonas aeruginosa 8
Staphylococcus aureus* 5
Enterobacter cloacae 4
Enterococcus spp. 3
Acinetobacter woffii 2
Bacillus spp. 2
Micrococcus spp. 2
Neisseria spp 2
Pantoea agglomerans 2
Vancomycin-resistant Enterococcus faecium (VRE) 2
Arthrobacter spp. 1
Burkholderia cepacia 1
Strep. Pneumoniae 1
Corynebacterium spp. 1
Kocuria kristinae 1
Leuconostoc spp. 1
MR-Klebsiella spp. 1
MR-Pseudomonas spp. 1
Proteus spp. 1
Ralstonia pickettii 1
Candida albicans 1
BSI = bloodstream infection
CoNS = coagulase-negative Staphylococci
MRSE = methicillin-resistant coagulase-negative Staphylococci
MR = multiresistant in vitro
(here: to piperacillin, aminogylcosides and to 3rd generation cephalosporines)
* No MRSA was detected.BMC Infectious Diseases 2008, 8:70 http://www.biomedcentral.com/1471-2334/8/70
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transplantation. This is in line with a prospective surveil-
lance study in pediatric patients treated in an STC unit
conducted by Laws et al. [12]. Using the surveillance pro-
tocol of the German National Reference Centre for Sur-
veillance of HAI for adults [15], 34 pediatric and 39 adult
patients were followed for 24 months. The incidence of
HAI during neutropenia (1,156 neutropenic days) was
38.9 per 1,000 days, without significant difference
between the groups. The Oncopaed NKI module may be
used for the surveillance of late onset infections after SCT,
in particular invasive aspergillosis [25].
Overall, the attributable mortality in our study was sur-
prisingly low, mainly due to a low mortality in patients
with BSIs. The outcome of BSIs in pediatric oncology
patients has improved over the last decade, mainly due to
early aggressive treatment in any suspected case of sepsis
and due to advances in intensive care in this particular
population [26].
The proportion of resistant isolates in the BSIs was also
surprisingly low, considering the increasing proportion of
resistant isolates in studies from other countries [13].
Wisplinghof et al. [27] determined antimicrobial suscep-
tibilities of nosocomial BSI isolates in pediatric patients in
the US SCOPE project. As in our study, Gram-positive
pathogens accounted for most (65%) of the cases, Gram-
negative pathogens for 24% and fungi for 11%. We iden-
tified only a single case of candidemia. In Wisplinghof's
study, the proportion of MRSA increased from 10% in
1995 to 29% in 2001 [27]. Vancomycin-resistance was
seen in 11% of E. faecium isolates (VRE). In our study, no
BSI was caused by MRSA, but 2 of 5 E. faecium BSI were
caused by VRE. In the study of Raymond et al. [13], the
prevalence of antimicrobial resistance depended on the
type of unit. Up to 26% of S. aureus and 89% of CoNS
were methicillin-resistant (MRSA, MRSE), and 38% of K.
pneumoniae  expressed an extended-spectrum beta-lacta-
mase (ESBL) [28].
The high mortality in patients with invasive aspergillosis,
in particular in those patients with disseminated disease,
is still a matter of great concern. The recognition of the
role of external reservoirs and acute exposure to fungal
spores as well as the expanding scope of the agents avail-
able for antifungal prophylaxis may contribute to a higher
success rate in the prevention of these often fatal infec-
tions in high-risk pediatric cancer patients [18].
Based on our experience with a norovirus outbreak in
pediatric oncology patients [29] and our recent investiga-
tion of rotavirus infections in a matched pairs analysis
[30], the surveillance of gastrointestinal HAI in pediatric
cancer patients should include at least rotavirus, norovi-
rus, and CDAD, which is, however, difficult to define in
this population [31].
Our results confirm the observation of Dettenkofer et al.
[15] that a remarkable proportion of all symptomatic
patients with CDAD do not suffer from neutropenia at the
time of diagnosis. The empirical antimicrobial regimen of
fever and neutropenia does not cover C. difficile and fos-
ters the production of C. difficile toxins [32]. Discontinu-
ation of the offending antibiotic as a general treatment
principle in patients with CDAD [33] is not feasible in
patients with neutropenia. Recently, hypervirulent noso-
comially transmitted C. difficile isolates have been
described in several countries, causing increased morbid-
ity, length of hospital stay, and mortality in adult patients
[34].
Considering the significant morbidity of affected patients,
the possibility of outbreaks, and the emerging threat of
hypervirulent isolates, it seems mandatory to implement
continuous prospective surveillance of CDAD in pediatric
cancer patients [35].
Prospective surveillance modules, such as that presented
here, may be utilized to detect early (< 30 days) or late (up
to 2 years in presence of prosthetic devices) SSI. Gaur et al.
[36] retrospectively investigated infections complicating
limb-sparing surgery (104 procedures) in 103 children
and young adults with bone malignancies. They found a
high incidence of infections (median 4%; range 0–13%),
including local SSI in 67% and secondary bacteremia in
21% of patients. Patients who developed deep infections
were more likely to undergo amputation (odds ratio [OR]
24.0; 95% CI 5.1–114.0; P < 0.001) and were less likely to
have good functional outcomes (OR 0.02; 95%CI 0.002–
0.15;  P  < 0.001). Different strategies of antimicrobial
prophylaxis and antibacterial management in tumor-
related orthopedic surgery may – as well as in other surgi-
cal interventions [37] – be evaluated prospectively in
future studies [38].
The fact that we defined as nosocomially acquired infec-
tion only those RSV infections in which the first symp-
toms occurred after at least 5 days of inpatient care did not
allow the inclusion of some cases of nosocomial RSV
infection, since the exact onset is sometimes difficult to
determine. Although RSV is easily communicable and has
been the cause of fatal outbreaks even in the setting of all-
ogenic BMT [39], there is still no evidence-based antiviral
treatment option [40]. Therefore, the early detection of
this pathogen and immediate contact/droplet isolation of
infected patients and their relatives is of utmost impor-
tance.BMC Infectious Diseases 2008, 8:70 http://www.biomedcentral.com/1471-2334/8/70
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Our results demonstrate that microbiologic testing in
pediatric cancer patients with pneumonia, with the excep-
tion of mechanically ventilated patients with acute respi-
ratory failure, often fails to identify the causative agent [6].
In the light of the profoundly restricted time budget of
infection control personnel, the inclusion of pneumonias
without a confirmed pathogen, blood-culture negative
BSIs, urinary tract infections, and nFUOs should be recon-
sidered critically in surveillance efforts in this population.
While we did not control for confounding variables such
as demographic characteristics of the patients, duration of
neutropenia or illness severity, further studies are needed
to confirm that participation in such a surveillance study
results in a significant decrease in HAI rates. This was not
an interventional study and each participating center
decided on its own responsibility about any practical con-
sequence related to the reported HAI rates.
Today, HAIs are considered to be important adverse out-
comes in terms of increased morbidity and mortality,
postponed chemotherapy treatment cycles, as well as pro-
longed duration of hospital stay and additional costs from
the perspective of the caregiver. All efforts to prevent HAI
and to contain the nosocomial spread of pathogens are
critical aspects of patient's safety in the hospital environ-
ment [41]. Thus, the prospective surveillance of HAI and
comparison with standardized rates should be recognized
as a fundamental component of quality assurance and
control in the treatment of immunocompromized pediat-
ric cancer patients.
Conclusion
Our multicenter study confirmed that pediatric cancer
patients are at an increased risk for specific HAIs, in partic-
ular vascular catheter-associated bloodstream infections.
It seems reasonable to implement a specific surveillance
protocol for HAI in this high risk population. Surveillance
efforts should not only focus on periods of profound neu-
tropenia. The prospective surveillance of HAI and com-
parison with cumulative multicenter results are
indispensable for targeted prevention of these adverse
events of anticancer treatment.
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